透過您的圖書館登入
IP:18.218.196.182
  • 期刊

Intravitreal Bevacizumab for Treating Exudative Retinal Detachment in Coats Disease

玻璃體內注射癌思停以治療柯氏症併發的滲出性視網膜剝離

摘要


本文宗旨:報告使用玻璃體內注射癌思停以治療一位柯氏症併發滲出性視網膜剝離的病例。方法:回顧性病例報告。結果:一位十五歲男孩的左眼罹患第三期早期柯氏症,併發視網膜下水腫與滲出性視網膜剝離,接受了一次玻璃體內注射癌思停治療。治療後中央視網膜厚度由882μm進步到347μm,三個月後滲出性視網膜剝離幾乎完全復位。最佳矯正視力由三十公分辨別手指數進步到3/60。結論:玻璃體內注射癌思停可有效的減少視網膜下積液,因而支持柯氏症的病理機轉可能與血管內皮生長因子相關因素有所關聯。

並列摘要


Background and purpose: To report a case of Coats disease with exudative retinal detachment treated with an intravitreal bevacizumab injection. Methods: Retrospective interventional case report. Results: A 15-year-old boy with early stage 3 Coats disease of the left eye with subretinal exudation and exudative retinal detachment underwent a single injection of intravitreal bevacizumab. A marked reduction in the central retinal thickness (882 to 347 μm) and nearly complete reattachment of retina were noted 3 months after treatment. The best corrected visual acuity improved from counting fingers at 30 cm to 3/60. Conclusions: Intravitreal bevacizumab effectively reduced the subretinal fluid and suggests a vascular endothelial growth factor-mediated component in the pathogenesis of Coats disease in this patient.

延伸閱讀